Second Ovulation Induction

NCT06502665 | Completed

• 1 other identifier: 3572
• Study Type: observational
• Target: 87
• Locations: 1 country
• Sites: 1

Brief Summary

Studies reported various risk factors for inadequate ovulation induction such as body mass index, low ovarian reserve, low baseline FSH and LH, and previous use of contraception or agonist. The flexibility to use human chorionic gonadotropin (hCG) or gonadotropin-releasing hormone agonist (GnRHa) in ovulation induction for antagonist protocol or progestin primed ovarian stimulation (PPOS) is an advantage helping fertility doctors to decrease the risk of ovarian hyperstimulation syndrome. However, luteinizing hormone (LH) levels \<15UI/L and progesterone ≤11.13nmol/L eight to twelve hours post GnRHa trigger were highly correlated to failed oocyte pickup (FOP). Rescue hCG have been found to increase favorable outcomes in patients with FOP. The presence of false FOP could be due pharmaceutical reasons and human error. Genuine FOP could be due to intrinsic ovarian pathology. The FOP is defined as the absence of oocytes after ovarian stimulation and follicular aspiration. It is an uncomfortable situation for the patient and medical team to deal with due to the apparent expectations of favorable results. Ovulation induction could be via GnRHa, HCG, or both in antagonist protocol and PPOS protocol. Long or short agonist protocol could be triggered only via HCG.

Conditions

IVF; Infertility

Outcome Measures

Primary Outcomes (1)

• Oocyte pick-up at retrieval

  Number of retrieved oocytes after second ovulation induction in patients with FOP

  36 hours after ovulation triggering

Secondary Outcomes (1)

• Timing of ovulation triggering

  24 to 36 hours after ovulation triggering

Interventions

Women having had second ovulation induction after failed oocyte pick-up OTHER

IVF success is defined by the number of retrieved oocytes. Identifying women at risk of failed oocyte pick-up at the first oocyte pick-up and optimizing their ovulation induction could enhance outcomes

Eligibility Criteria

• Gender Eligibility Details: Women able to have oocyte retrieval after in-vitro fertilization
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Electronic medical record from 2018 to 2023 of patients having undergone an IVF cycle

You may qualify if:

• Participants with no oocytes retrieved in the first ovum pick-up

You may not qualify if:

• Error in trigger medication or timing by the patient/ medical team
• Major absence of information (primary objective, trigger medication, time interval of trigger and ovum pick-up

Sponsors & Collaborators

• Clinique Ovo: lead

Study Sites (1)

Clinique Ovo

Montreal, Quebec, H4P 2S4, Canada

Location

MeSH Terms

Conditions

Infertility

Condition Hierarchy (Ancestors)

Genital Diseases; Urogenital Diseases

Study Officials

• Simon Phillips, PhD

  Clinique Ovo

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 9, 2024
• First Posted: July 16, 2024
• Study Start: July 4, 2024
• Primary Completion: July 30, 2024
• Study Completion: May 20, 2025
• Last Updated: September 10, 2025

Record last verified: 2024-07

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)